Swedish Orphan Biovitrum AB SOBI

As per 30 September 2026, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,636,514 shares. All shares are common shares. The total number of votes is 357,636,514. The increase in the number of shares and votes results from the issue of 223,677 class C shares. The class C shares were issued for the purpose of ensuring fulfilment of commitments under the long-term incentive programme for permanent employees (the All Employee Programme) and have by virtue of t

Sobi® (STO: SOBI) today announced that new clinical data on Gamifant® (emapalumab) in primary haemophagocytic lymphohistiocytosis (HLH) will be presented at the 2026 Annual Meeting of the Histiocyte Society (HS2026), taking place 26-29 September in Rotterdam, the Netherlands.

Aytu BioPharma, Inc. (AYTU) delivered earnings and revenue surprises of +77.27% and +39.45%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that the previously announced strategic partnership with Innate is now effective following the expiration of applicable antitrust waiting periods and completion of other conditions.

WALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to pacritinib for the treatment of VEXAS syndrome. Pacritinib is a dual IRAK1/JAK2 inhibitor currently in Phase ll development for VEXAS syndrome. Fast Track designation is designed to facilitate the development and expedite the review of medicines to treat seri

The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 6 May 2026 resolved on a directed issue of redeemable and convertible class C shares and to authorise the Board of Directors to resolve on the repurchase of all issued class C shares through an acquisition offer directed to all owners of class C shares in Sobi. The Board of Directors of Sobi has, as previously communicated, on 15 July 2026 resolved to, conditional upon subscription and payment from Svenska Handelsbanken

Why Swedish Orphan Biovitrum Stock Is Back In Focus Swedish Orphan Biovitrum (OM:SOBI) has drawn fresh attention after a new partnership with Innate Pharma to run the TELLOMAK-3 Phase 3 trial for lacutamab in cutaneous T cell lymphoma. See our latest analysis for Swedish Orphan Biovitrum. The lacutamab agreement lands after a softer month for Swedish Orphan Biovitrum’s share price, which is down about 3.4% over 30 days. However, the year-to-date share price return of 33.3% and 1-year total...

Swedish Orphan Biovitrum has delivered a strong share price run over the past five years, yet its current valuation checks lean expensive rather than cheap. For investors looking at the stock today, the key issue is how to balance that track record with a low overall value score and recent deal activity. The stock has returned 157.1% over five years, which puts a clear focus on whether recent gains already reflect much of Swedish Orphan Biovitrum's potential. The licensing agreement for...

Innate is planning to begin a Phase III confirmatory trial on lacutamab as it vies for the drug’s accelerated approval in a rare subset of CTCL.

Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL.

German vaccine manufacturer BioNTech has found a successor to take over as chief executive officer from co-founder Uğur Şahin. Guido Oelkers will take up the post by February 1 next year at the latest, the company announced on Monday.

Mainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive Officer (“CEO”), who will take office by February 1, 2027, at the latest. Succeeding Prof. Ugur Sahin, M.D., Guido Oelkers will join BioNTech from the global Nasdaq Stockholm-listed biopharmaceutical company Swedish Orphan Biovitrum AB (STO: SOBI, “Sobi”), where he has se

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announces that Guido Oelkers has informed the Board of Directors that he has decided to step down as Chief Executive Officer of Sobi to take up another position outside Sobi.

Swedish Orphan Biovitrum AB (BIOVF) reports a robust 29% revenue growth, driven by key product performances and strategic pipeline advancements, despite facing competitive and regulatory challenges.

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter of 2026.